Letters to the Editor

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Biostatistics
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Radiation Oncology
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Lymphoma and Myeloma
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Lymphoma and Myeloma
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Lymphoma and Myeloma
Haematologica Early view Nov 17, 2022 https://doi.org/10.3324/haematol.2022.281954